Skip to main content
COMPLETED RESEARCH: PRACTICE MANAGEMENT
Abstract #PM04

The Incidence of Coring Between the Traditional Syringe and Needle Compounding Technique and Closed-System Transfer Devices

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Infusion Issues

Presenter: Kathryn French, BS, PharmD, MBA, Pharmacy Resident, Canton Potsdam Hospital

Co-Authors: Delaney Frears, PharmD Candidate, Albany College of Pharmacy and Health Sciences; Sahil Kamboj, PharmD, Albany College of Pharmacy; Regina Scott, PharmD, BCPS, Canton Potsdam Hospital; Ryan Titus, PharmD, BCPS, BCOP, Canton Potsdam Hospital

Background: Closed-system transfer devices (CSTDs) are used to transfer medication from one reservoir to another, while reducing the risk of hazardous drug exposure to the person mixing and administering. Coring is the production of rubber fragments that occur during manipulations within the intravenous drug compounding process. These fragments may be drawn up with the medication and injected into patients.

Objective: To compare the incidence of coring between CSTDs (PhaSeal and Equashield) and the traditional technique of intravenous drug preparation.

Methods: The institutional review board approved this case-control, independent group study and request for exclusion of informed consent was granted. Over the course of 9 months, pharmacists and pharmacy technicians working in the oncology infusion pharmacy closely identified and recorded the occurrence of coring with PhaSeal and Equashield during hazardous drug mixing. Coring was also monitored when using the traditional needle and syringe technique for nonhazardous drug preparation. All cores were filtered before admixture addition. Statistical significance was analyzed via the chi-squared test and association was determined by risk ratio (RR). The absolute risk reduction and numbers needed to harm were also calculated.

Results: Coring occurred in 3 of 625 (0.48%) vials with traditional needle and syringe technique, 110 of 1705 (6.45%) vials with PhaSeal, and 42 of 1760 (2.39%) vials with Equashield. The traditional syringe and needle compounding technique resulted in statistically significant decrease in coring compared with Equashield (P = .003; RR = 0.201; 95% confidence interval [CI], 0.063-0.647) or PhaSeal devices (P <.0001; RR = 0.074; 95% CI, 0.024-0.233). Equashield resulted in less coring compared with PhaSeal (P <.0001; RR = 0.37; 95% CI, 0.261-0.524). The absolute risk reduction was 4%, and the number needed to harm was 25.

Conclusion: The risk of cores injected into patients include thromboembolisms and organ damage.1 This study confirmed the increased occurrence of coring when using CSTDs.1 In addition, it demonstrated differences in coring incidences between CSTDs, as well as the need for continual education of pharmacy and nursing staff regarding the identification of cores and resulting filtration requirements.

  1. Wani T, Wadhwa A, Tobias JD. The incidence of coring with blunt versus sharp needles. J Clin Anesth. 2014;26:152-154.
Related Items
Assessing Student Pharmacists’ Knowledge and Perceptions of Financial Toxicity Concepts Introduced in an Oncology Pharmacotherapy Course
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Biodistribution and Shedding Analysis Following RP1 Oncolytic Immunotherapy Dosing in Patients From the IGNYTE Clinical Trial: Implications for Oncology Pharmacists
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Characterizing Second-Line and Beyond Treatments for Primary Central Nervous System Lymphomas
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Coordinating Better Outcomes in Multiple Myeloma: An Educational Initiative to Elevate Pharmacist Leadership in Novel Antibodies and CAR-T Therapy
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Darolutamide, Enzalutamide, and Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer Patients in the United States (DEAR): Comparative Real-World Evidence
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Dosing, Safety, and Pharmacokinetics of Combination Therapy With Darolutamide, Androgen-Deprivation Therapy, and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer in the ARASENS Study
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Evaluating Patient Hesitancy in Receiving a Second Dose of Evusheld (Tixagevimab and Cilgavimab) for COVID-19 Prevention After a Food and Drug Administration Dosing Recommendation Update
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
First-Line Nivolumab + Ipilimumab + Chemotherapy Versus Chemotherapy Alone in Metastatic Non–Small Cell Lung Cancer: CheckMate 9LA 4-Year Clinical Update
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Impact of Frailty on Outcomes After CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Improving Post-Transplant Vaccination Compliance via Implementation of a Clinical Pharmacist–Managed Service
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts